— Know what they know.
Not Investment Advice

EVLO OTC

Evelo Biosciences, Inc.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: -80.0% 1Y: -80.0% 3Y: -100.0% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 54 · $1898 mcap · 19M float · 0.0031% daily turnover · Short 100% of daily vol

Balance Sheet Trends

Total Assets
$64M -26.7% ▼
5Y CAGR: +8.0%
Total Liabilities
$69M -12.3% ▼
5Y CAGR: +37.0%
Shareholders Equity
-$5M -157.6% ▼
Cash & Investments
$48M -30.0% ▼
5Y CAGR: +4.6%
Total Debt
$51M -9.2% ▼
5Y CAGR: +38.7%
Net Debt
$3M +126.3% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2018FY2019FY2020FY2021FY2022
— Assets —
Cash$148M$78M$69M$68M$48M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$148M$78M$69M$68M$48M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0-$3M$250K$0$4M
Total Current Assets$148M$78M$71M$71M$52M
Property, Plant & Equip.$7M$8M$18M$16M$12M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$5M$5M$4M$1M$1M
Total Non-Current Assets$12M$13M$22M$17M$13M
Total Assets$160M$91M$91M$88M$64M
— Liabilities —
Accounts Payable$2M$620K$1M$2M$2M
Short-Term Debt$0$0$0$2M$0
Deferred Revenue$0$0$0$13M$0
Other Current Liabilities$8M$9M$8M$742K$2M
Total Current Liabilities$9M$10M$20M$17M$12M
Long-Term Debt$12M$20M$30M$47M$44M
Other Non-Current Liab.$1M$1M$284K$0$659K
Total Non-Current Liabilities$14M$21M$40M$62M$57M
Total Liabilities$23M$31M$60M$79M$69M
— Equity —
Common Stock$32K$32K$47K$54K$111K
Retained Earnings-$113M-$199M-$293M-$415M-$529M
Accumulated OCI-$18K-$91M$0$0$0
Total Stockholders Equity$137M$60M$30M$9M-$5M
Total Liabilities & Equity$160M$91M$91M$88M$64M
— Key Metrics —
Total Debt$12M$20M$40M$56M$51M
Net Debt-$136M-$58M-$29M-$12M$3M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms